Genezen to Acquire uniQure’s Gene Therapy Manufacturing Site

• Genezen acquires uniQure’s commercial gene therapy operations in Lexington, MA.

• Acquisition includes strategic supply agreements for uniQure’s clinical portfolio and CSL’s commercial HEMGENIX® product.

Genezen, a gene therapy CDMO, has announced an agreement to acquire uniQure’s commercial gene therapy operations in Lexington, MA. The acquisition includes a state-of-the-art manufacturing facility and a world-class team of employees. This transaction will enable Genezen to enhance its manufacturing capabilities and provide comprehensive support to its clients from preclinical development through to commercial manufacturing.

The acquisition involves strategic supply agreements for uniQure’s clinical portfolio and CSL’s commercial HEMGENIX® product, the first gene therapy approved in the U.S. and Europe for treating adults with severe and moderately severe Hemophilia B. The Lexington site, located near Boston, is a commercially-licensed viral vector facility. This site will serve as Genezen’s global AAV center of excellence, complementing its existing operations in Indianapolis, IN.

Steve Favaloro, President and CEO of Genezen, stated, “I am thrilled to welcome the Lexington team and the addition of a state-of-the-art, licensed viral vector manufacturing facility to Genezen. This acquisition significantly enhances Genezen’s scale and differentiated capabilities, directly aligned with our mission to advance cell and gene therapies by providing top-tier, science-driven development and manufacturing solutions.”

Matt Kapusta, CEO of uniQure, commented, “uniQure has been a pioneer in gene therapy manufacturing for the past 15 years, and we are pleased to have found a partner in Genezen to take the facility and team into its next phase of growth.”

Mike Deem, Head of CSL Behring Operations, added, “We are excited to expand our relationship with Genezen and have them take on HEMGENIX® commercial supply from the Lexington manufacturing operation.”

The transaction will be partially funded by additional growth equity from Ampers and Capital Partners. Favaloro expressed gratitude for Ampersand’s support, noting that the financing will allow Genezen to grow its multi-site operations and execute its long-term growth strategy.